Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Otsuka Pharmaceutical
Biotech
Otsuka pens $420M deal for Asia rights to 4DMT gene therapy
4DMT has sold the Asia-Pacific rights to its eye gene therapy to Otsuka, securing $85 million in cash to fund the asset’s phase 3 development.
James Waldron
Oct 31, 2025 5:09am
Otsuka inks $613M deal for Swedish biotech's IL1RAP antibodies
Jul 16, 2025 1:37pm
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Jul 8, 2025 10:17am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
Otsuka's Taiho pays $400M to buy Swiss ADC partner
Mar 17, 2025 8:10am
